BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BGB-43395 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BGB-43395\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07820891-2389@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20261122
DTEND;VALUE=DATE:20261123
SUMMARY:BGB-43395: Phase 1 readout est. (NCT07820891)
DESCRIPTION:BGB-43395\, phase 1.\nStudy: A Trial in Healthy Participants to
  Assess Drug Interaction Potential of BGB-43395\nEstimated primary complet
 ion: 22 November 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bgb-43395#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07820891
URL:https://assetmemo.bio/drug/bgb-43395#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06756932-2389@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:BGB-43395: Phase 1 readout est. (NCT06756932)
DESCRIPTION:BGB-43395\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Recept
 or Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-
 ) Metastatic Breast Cancer\nEstimated primary completion: 30 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bgb-43395#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06756932
URL:https://assetmemo.bio/drug/bgb-43395#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226349-2389@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:BGB-43395: Phase 1 readout est. (NCT07226349)
DESCRIPTION:BGB-43395\, phase 1.\nStudy: A Study of BG-75098 Alone and in C
 ombination With Other Agents in Adults With Advanced Solid Tumors\nEstimat
 ed primary completion: 1 November 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/bgb-43395#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07226349
URL:https://assetmemo.bio/drug/bgb-43395#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492641-2389@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:BGB-43395: Phase 3 readout est. (NCT07492641)
DESCRIPTION:BGB-43395\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients Wit
 h Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Pri
 or Treatment for Advanced or Metastatic Disease\nEstimated primary complet
 ion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bgb-
 43395#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07492641
URL:https://assetmemo.bio/drug/bgb-43395#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120283-2389@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:BGB-43395: Phase 1 readout est. (NCT06120283)
DESCRIPTION:BGB-43395\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: BGB-43395 Alone or as Part of Combination Therapies in Participants Wit
 h Breast Cancer and Other Advanced Solid Tumors\nEstimated primary complet
 ion: December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 gb-43395#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06120283
URL:https://assetmemo.bio/drug/bgb-43395#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
